Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Travis Edward Grotz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7753-097X; OpenAlex author ID A5035664172. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid. Co-author DOI 10.1002/jso.70292↗
  2. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  3. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32020103↗
  4. The Emerging Role of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pancreatic Cancer. First author DOI 10.1002/jso.27880↗
  5. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14875-5↗
  6. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. Co-author DOI 10.1097/xcs.0000000000000704↗
  7. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  8. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenoc… Last author DOI 10.1245/s10434-023-14138-3↗
  9. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  10. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  11. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4144↗
  12. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinica… Co-author DOI 10.1016/j.jamcollsurg.2021.05.009↗
  13. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cornelius A. Thiels · 10 shared papers, 2021–2026 · strength 2.08
  2. Sean Patrick Cleary · 11 shared papers, 2020–2026 · strength 1.72
  3. Mark Joseph Truty · 11 shared papers, 2020–2026 · strength 1.72
  4. Michael L. Kendrick · 10 shared papers, 2020–2025 · strength 1.50
  5. Susanne Gray Warner · 7 shared papers, 2022–2026 · strength 1.27
  6. Jennifer A. Yonkus · 7 shared papers, 2021–2025 · strength 1.10
  7. Amro M. Abdelrahman · 5 shared papers, 2021–2025 · strength 0.75
  8. Roberto Alva‐Ruiz · 5 shared papers, 2021–2025 · strength 0.73
  9. Robert R. McWilliams · 4 shared papers, 2022–2025 · strength 0.62
  10. Jennifer L. Leiting · 3 shared papers, 2021–2025 · strength 0.44
  11. Hallbera Gudmundsdottir · 2 shared papers, 2023 · strength 0.36
  12. Amit Mahipal · 2 shared papers, 2022–2023 · strength 0.30
  13. Thorvardur Ragnar Halfdanarson · 2 shared papers, 2022 · strength 0.24
  14. Christopher Leigh Hallemeier · 2 shared papers, 2022 · strength 0.24
  15. Rondell Patrell Graham · 2 shared papers, 2022 · strength 0.24
  16. Wen Wee Ma · 2 shared papers, 2022 · strength 0.24
  17. Danielle K. DePeralta · 1 shared paper, 2025 · strength 0.24
  18. Sepideh Gholami · 1 shared paper, 2025 · strength 0.24
  19. Craig Devoe · 1 shared paper, 2025 · strength 0.24
  20. Oliver J. Standring · 1 shared paper, 2025 · strength 0.24
  21. Grace Wu · 1 shared paper, 2025 · strength 0.24
  22. Daniel A. King · 1 shared paper, 2025 · strength 0.24
  23. Matthew John Weiss · 1 shared paper, 2025 · strength 0.24
  24. Mustafa Raoof · 1 shared paper, 2025 · strength 0.24
  25. Douglas W. Mahoney · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.